Trial Profile
A Study to Evaluate Whether Genetic and Non Genetic Risk Factors Influence Response to Ranibizumab Treatment for Exudative Age Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 29 Apr 2016 New trial record